The use of standard methodology for determination of antifungal activity of natural products against medical yeasts Candida sp and Cryptococcus sp.

Brazilian Journal of Microbiology

Volumn 38, Issue 3, 2007, Pages 391-397

  Scorzoni, Liliana ^a   Benaducci, Tatiane ^a   Almeida, Ana Marisa Fusco ^a   Silva, Dulce Helena Siqueira ^a   Bolzani, Vanderlan Da Silva ^a   Gianinni, Maria José Soares Mendes ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Antifungal activity; Candida sp; Cryptococcus sp.; Natural products

Indexed keywords

CANDIDA; CRYPTOCOCCUS SP.;

EID: 36248959281     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822007000300001     Document Type: Review

References (60)

1. Alves, T.M.; Silva, A.F.; Brandao, M.; Grandi, T.S.; Smania, E.; Smania Junior A.; Zani, C.L. (2000). Biological screening of Brazilian medicinal plants. Mem. Inst. Oswaldo. Cruz, 95(3): 367-73.
2. Arthington-Skaggs, B.A.; Lee-Yang, W.; Ciblak, M.A.; Frade, J.P.; Brandt, M.E.; Hajjeh, R.A.; Harrison, L.H.; Sofair, A.N.; Warnock, D.W; Candidemia Active Surveillance Group. (2002). Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determination and evaluation of sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents. Chemother., 46(8): 2477-81.
3. Barberino, M.G.; Silva, N.; Reboucas, C.; Barreiro, K.; Alcantara, A.P.; Netto, E. M, Albuquerque, L.; Brites, C. (2006). Evaluation of Blood Stream Infections By Candida In Three Tertiary Hospitals In Salvador, Brazil: A Case-Control Study. Braz. J. Infect Dis., 10(1): 36-40.
4. Bartner, A.; Pfeiffer, K.P.; Batner, H. (1994). Applicability of disc diffusion methods required by the pharmacopoeias for testing antibacterial activity of natural compounds. Pharmazie, 49: 512-516.
5. Chryssanthou, E.; Cuenca-Estrella. M. (2002) Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol., 40(10): 3841-4.
6. Clardy, J.; Walsh, C. (2004). Lessons from natural molecules. Nature, 432(7019): 829-37.
7. Colombo, A.L.; Nucci, M.; Park, B.J.; Nouer, S.A.; Arthington-Skaggs, B.; Da Matta, D.A.; Warnock, D.; Morgan, J. Brazilian Network Candidemia Study. (2006) Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol., 44(8): 2816-23.
8. Colvard, M.D.; Cordell, G.A.; Villalobos, R.; Sancho, G.; Soejarto, D.D.; Pestle, W.; Echeverri, T.L.; Perkowitz, K.M.; Michel, J. (2006). Survey of medical ethnobotanicals for dental and oral medicine conditions and pathologies. J. Ethnopharmacol., 107(1): 134-42.
9. Cordell, G.A.; Colvard, M.D. (2005). Some thoughts on the future of ethnopharmacology. J. Ethnopharmacol., 100(1-2): 5-14.
10. Cos, P.; Vlietinck, A.J.; Berghe, D.V.; Maes, L. (2006) Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. J. Ethnopharmacol., 106(3): 290-302.
11. Duarte, M.C.; Figueira, G.M.; Sartoratto, A.; Rehder, V.L.; Delarmelina, C. (2005). Anti-Candida activity of Brazilian medicinal plants. J. Ethnopharmacol., 97(2): 305-11
12. Espinel-Ingroff, A.; Pfaller M.A.; Messer, S.A.; Knapp, C.C.; Killian, S.; Norris, H.A.; Ghannoum, M.A. (1999). Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeast-like organisms. J. Clin. Microbiol., 37: 591-595.
13. Espinel-Ingroff, A.; Pfaller, M.A.; Messer, S.A.; Knapp, C.C.; Holliday, N.; Killian, S. (2004). Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol., 2: 718-721.
14. European Committee on Antibiotic Susceptibility. Method for determination of minimal inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Discussion document EDis 7.1. (2002) Taufkirchen, Germany: European Society of Clinical Microbiology and Infectious Diseases.
15. Fusco-Almeida, A.M.; Matsumoto, M.T.; Baeza, L.C.; Oliveira R.B.S.; Kleiner, A.A.P.; Melhem M.S.C.; Mendes-Giannini M.J.S. and the Laboratory Group on Cryptococcosis. (2006). Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil. FEMS Yeast Research (in press)
16. Goncalves, R.H.; Miranda, E.T.; Zaia, J.E.; Giannini, M.J. (2006). Species diversity of yeast in oral colonization of insulin-treated diabetes mellitus patients. Mycopathologia., 162(2):83-9.
17. Graybill, J.R. (1996). The future of antifungal therapy. Clin. Infect. Dis., Suppl 2: S166-78
18. Gulluce, M.; Aslan, A.; Sokmen, M.; Sahin, F.; Adiguzel, A.; Agar G.; Sokmen A. (2006). Screening the antioxidant and antimicrobial properties of the lichens Parmelia saxatilis, Platismatia glauca, Ramalina pollinaria, Ramalina polymorpha and Umbilicaria nylanderiana. Phytomedicine, 13(7): 515-21
19. Hadacek, F.; Greger, H. (2000) Testing of antifungal natural products: Methodologies, comparability of results and assay of choice. Phytochem Anal, 11: 137-147.
20. Hiemenz, J.W.; Walsh, T.J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis., Suppl 2: S133-44.
21. Holetz, F.B.; Pessini, G.L.; Sanches, N.R.; Cortez, D.A.; Nakamura, C.V.; Filho, B.P. (2002). Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. Mem. Inst. Oswaldo Cruz, 97(7): 1027-31.
22. Iscan, G.; Kirimer, N.; Kurkcuoglu, M.; Baser, K.H.; Demirci, F. (2002). Antimicrobial screening of Mentha piperita essential oils. J. Agric. Food. Chem., 50(14): 3943-6.
23. Kirk, S.M.; Callister, S.M.; Lim, L.C.; Schell, R.F. (1997). Rapid susceptibility testing of Candida albicans by flow cytometry. J. Clin. Microbiol., 35(2): 358-63.
24. Krick, J.A. (1981). Familial cryptococcal meningitis. J. Infect Dis., 143(1): 133.
25. Larcher, G.; Morel, C.; Tronchin, G.; Landreau, A.; Seraphin, D.; Richomme, P.; Bouchara, J.P. (2004) Investigation of the antifungal activity of caledonixanthone E and other xanthones against Aspergillus fumigatus. Planta Med., 70(6): 569-71.
26. Lee, K.H. (1999). Anticancer drug design based on plant-derived natural products. J. Biomed. Sci., 6(4): 236-50.
27. Li, X.C.; Jacob, M.R.; Elsohly, H.N.; Nagle, D.G.; Smillie, T.J.; Walker, L.A.; Clark, A.M. (2003). Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia. J. Nat. Prod., 66(8): 1132-5.
28. Maertens, J.A.; Boogaerts, M.A. (2000). Fungal cell wall inhibitors: emphasis on clinical aspects. Curr. Pharm. Des., 6(2): 225-39.
29. Matsumoto, M.T.; Fusco-Almeida, A.M.; Baeza, L.C.; Melhem, M.S.C.; Mendes-Giannini, M.J.S. (2006). Genotyping, serotyping and determination of mating-type of Cryptococcus neoformans clinical isolates from São Paulo State, Brazil. Rev. Inst. Med. Trop., São Paulo (in press).
30. Morace, G.G.; Amato, F.; Bistoni, G.; Fadda, P.; Marone, M.T.; Montagna, S.; Oliveri, L.; Polonelli, R.; Rigoli, I.; Mancuso, S.; La Face, L.; Masucci, L.; Romano, C.; Napoli, D.; Tato, M.G.; Buscema, C.M.C.; Belli, M.M.; Piccirillo, S.; Conti, S.; Covan, F.; Fanti, C.; Cavanna, F. D'Alo, Pitzurra, L. (2002). Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J. Clin. Microbiol., 40: 2953-2958.
31. National Committee For Clinical Laboratory Standards NCCLS. (1992). Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. M27-P. NCCLS. Villanova.
32. nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
33. National Committee for Clinical Laboratory Standards. (2004). Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
34. National Committee for Clinical Laboratory Standards. (1997). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards; Wayne, PA.
35. National Committee For Clinical Laboratory Standards. (2002). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards; Wayne, Pa.
36. Nguyen, M.H.; Yu, C.Y. (1999). Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. J. Clin. Microbiol., 37(1): 141-5.
37. Passos, X.S.; Santos, Das. C.; Ferri, P.H.; Fernandes, Ode. F.; Paula, T.F.; Garcia, A.C.; Silva, Mdo. R. (2002). Antifungal activity of Caryocar brasiliensis (Caryocaraceae) against Cryptococcus neoformans. Rev. Soc. Brás. Med. Trop., 35(6): 623-7.
38. Patwardhan, B.; Warude, D.; Pushpangadan, P.; Bhatt, N. (2005) Ayurveda and traditional Chinese medicine: a comparative overview. Evid. Based Complement. Alternat. Med., 2(4): 465-73.
39. Pauli, A. (2006). Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils. Med. Res. Rev., 26(2): 223-68.
40. Pauli, A.; Kubeczka, K.H. (1996). Evaluation of inhibitory data of essential oil constituents obtained with different microbiological testing methods. In: Franz, C.; Mathe, A.; Buchbauer, G. editors. Essential Oils: Basic and Applied Research. Carol Stream: Allured Pub. Corp., pp.33-36.
41. Perea, S.; Patterson, T.F. (2002).Antifungal resistance in pathogenic fungi. Clin. Infec. Dis., 35(9): 1073-80.
42. Pina-Vaz, C.; Costa-de-Oliveira, S.; Rodrigues, A.G.; Espinel-Ingroff, A. (2005). Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J. Clin. Microbiol., Sep. 43(9): 4674-9.
43. Pina-Vaz C.; Sansonetty, F.; Rodrigues, A.G.; Costa-de-Oliveira, S.; Martinez-de-Oliveira, J.; Fonseca, A.F. (2001). Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J. Med. Microbiol., 50(4): 375-82
44. Pina-Vaz, C.; Sansonetty, F.; Rodrigues, A.G.; Costa-Oliveira, S.; Tavares, C.; Martinez-de-Oliveira, J. (2001) Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin. Microbiol. Infect., 7(11): 609-18.
45. Rahalison, L.; Hamburger, M.; Monod, M.; Frenk, E.; Hostettmann, K. (1994). Antifungal tests in phytochemical investigations: comparison of bioautographic methods using phytopathogenic and human pathogenic fungi. Planta Med., 60(1): 41-4.
46. Ramani, R.; Chaturvedi, V. (2000). Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob. Agents. Chemother., 44(10): 2752-8.
47. Revankar, S.G.; Kirkpatrick, W.R.; Mcatee, R.K.; Fothergill, A.W.; Redding, S.W.; Rinaldi, M.G.; Patterson, T.F. (1998). Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J. Clin. Microbiol., 36(1): 153-6.
48. Rex, J.H.; Pfaller, M.A.; Walsh, T.J.; Chaturvedi, V.; Espinel-Ingroff, A.; Ghannoum, M.A.; Gosey, L.L.; Odds, F.C.; Rinaldi, M.G.; Sheehan, D.J.; Warnock, D.W. (2001). Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev., 14(4): 643-58.
49. Rios, J.L.; Recio, M.C.; Villar, A. (1988). Screening methods for natural products with antimicrobial activity: a review of the literature. J. Ethnopharmacol., 23(2-3): 127-49.
50. Rios, J.L.; Recio, M.C. (2005). Medicinal plants and antimicrobial activity. J Ethnopharmacol., 100(1-2): 80-4.
51. Romano, L.; Battaglia, F.; Masucci, L.; Sanguinetti, M.; Posteraro, B.; Plotti, G.; Zanetti, S.; Fadda, G. (2005). In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates. J. Antimicrob Chemother., 55(1): 110-4.
52. Ross, Z.M.; O'gara, E.A.; Hill, D.J.; Sleightholme, H.V.; Maslin, D.J. (2001). Antimicrobial properties of garlic oil against human enteric bacteria: evaluation of methodologies and comparisons with garlic oil sulfides and garlic powder, Appl. Environ. Microbiol., 67(1): 475-80.
53. Rox, B.; Rukayadi, Y.; Yong, D.; Hwang, J.K. (2006). In vitro anticandidal activity of xanthorrhizol isolated from Curcuma xanthorrhaiz. J. Antimicrob. Chemother., 57(6): 1231-4.
54. Salgueiro, L.R.; Pinto, E.; Goncalves, M.J.; Pina-Vaz, C.; Cavaleiro, C.; Rodrigues, A.G.; Palmeira, A.; Tavares, C.; Costa-De-Oliveira S.; Martinez-De-Oliveira, J. (2004). Chemical composition and antifungal activity of the essential oil of Thymbra capitata. Planta Med., 70: 572.
55. Souza, L.K.; De Oliveira, C.M.; Ferri, P.H.; De Oliveira Junior, J.G.; De Souza Junior, A.H.; Fernandes, Ode. F.; Silva, Mdo. R. (2003). Antimicrobial activity of Hyptis ovalifolia towards dermatophytes. Mem. Inst. Oswaldo Cruz, 98(7): 963-5.
56. Subramanian, S.; Mathai, D. (2005). Clinical manifestations and management of cryptococcal infection. J. Postgrad. Med., 51 Suppl 1: S21-6.
57. Terrell, C.L. (1999). Antifungal agents. Part II. The azoles. Mayo Clin. Proc., 74(1): 78-100.
58. Vale-Silva, L.A.; Buchta V. (2006). Antifungal susceptibility testing by flow cytometry: is it the future? Mycoses. 49(4):261-73.
59. Wenisch, C.; Parschalk, B.; Zedwitz-Liebenstein, K.; Wernsdorfer, W.; Graninger, W. (1997).The effect of artemisinin on granulocyte function assessed by flow cytometry. J. Antimicrob. Chemother., 39(1): 99-101.
60. Wingard, R.P.; Kubilis, L. Lee.; Yee, G.M.; White, L.; Walshe, R.; Bowden, E.; Anaissie, J.; Hiemenz; Lister, J. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis., 29(6): 1402-7.